STEPHEN P SQUINTO Insider Trading
Get free email notifications about insider trading for STEPHEN P SQUINTO.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of STEPHEN P SQUINTO. STEPHEN P SQUINTO is a EVP & Head of R&D in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP & Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP & Head of Research & Devel in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Chief Global Ops. Officer in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Global Ops. Officer in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Head of R&D in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Research & Development in ALEXION PHARMACEUTICALS INC ($ALXN) and a EVP, Research and Development in ALEXION PHARMACEUTICALS INC ($ALXN) and a Exec VP & Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and a Exec VP, Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and a Exec. VP & Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and an Executive VP in ALEXION PHARMACEUTICALS INC ($ALXN) and an Executive VP& Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and an Executive VP/Head of Research in ALEXION PHARMACEUTICALS INC ($ALXN) and a Director in Chemomab Therapeutics Ltd. ($ANCN) and a Director in Audentes Therapeutics, Inc. ($BOLD) and a Director in SpringWorks Therapeutics, Inc. ($SWTX) and a Head of Research and Dev in Passage BIO, Inc. ($PASG).
Address: C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE 06410 CT
Companies in which STEPHEN P SQUINTO is an Insider
ALEXION PHARMACEUTICALS, INC.
Trading Symbol: ALXNIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of STEPHEN P SQUINTO: EVP, Chief Global Ops. Officer, EVP, Global Ops. Officer, EVP, Head of R&D, EVP, Research & Development, EVP, Research and Development, EVP & Head of R&D, EVP & Head of Research & Devel, EVP & Head of Research, EVP, Head of Research, Executive VP& Head of
Holdings: 106,508 shares
Current Value: $13,603,202
Latest Transaction: Oct 28 2014
$ALXN Market Capitalization: $28.30B
$ALXN Previous Close: $127.72
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Audentes Therapeutics, Inc.
Trading Symbol: BOLDIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of STEPHEN P SQUINTO: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Oct 10 2017
$BOLD Market Capitalization: $337.82M
$BOLD Previous Close: $15.83
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Chemomab Therapeutics Ltd.
Trading Symbol: ANCNIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of STEPHEN P SQUINTO: Director
Holdings: 0 shares
Latest Transaction: Apr 21 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Passage BIO, Inc.
Trading Symbol: PASGIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of STEPHEN P SQUINTO: Head of Research and Dev
Holdings: 0 shares
Latest Transaction: Mar 02 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
SpringWorks Therapeutics, Inc.
Trading Symbol: SWTXIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of STEPHEN P SQUINTO: Director
Holdings: 144,959 shares
Latest Transaction: Apr 28 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of STEPHEN P SQUINTO
Sentiment: All, ALXN, BOLD, ANCN, PASG, SWTX
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 28 2021 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Sell | S | 76.20 | 19,231 | 1,465,437 | 125,728 | 145 K to 125.7 K (-13.27 %) |
Apr 28 2021 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Sell | S | 75.05 | 201 | 15,085 | 144,959 | 145.2 K to 145 K (-0.14 %) |
Apr 21 2021 | ANCN | Chemomab Therapeut ... | SQUINTO STEPHEN P | Director | Option Exercise | A | 27.26 | 23,768 | 647,916 | 23,768 | |
Apr 19 2021 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Sell | S | 75.01 | 1,057 | 79,291 | 145,160 | 146.2 K to 145.2 K (-0.72 %) |
Apr 19 2021 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Sell | S | 75.08 | 511 | 38,365 | 146,217 | 146.7 K to 146.2 K (-0.35 %) |
May 22 2020 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Option Exercise | A | 38.03 | 7,464 | 283,856 | 7,464 | |
Mar 13 2020 | SWTX | SpringWorks Therap ... | SQUINTO STEPHEN P | Director | Option Exercise | A | 28.76 | 20,000 | 575,200 | 20,000 |